Bellevue Group AG - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.

Quarter-by-quarter ownership
Bellevue Group AG ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$52,288,000
-14.4%
1,900,000
+5.6%
0.84%
-3.3%
Q2 2023$61,074,000
-5.7%
1,800,0000.0%0.87%
-7.3%
Q1 2023$64,764,000
-19.3%
1,800,0000.0%0.94%
-11.7%
Q4 2022$80,226,000
+58.6%
1,800,0000.0%1.06%
+46.7%
Q3 2022$50,598,000
+102.9%
1,800,000
+94.6%
0.73%
+105.7%
Q2 2022$24,938,000925,0000.35%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q1 2023
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders